HM 99462
Alternative Names: HM-99462Latest Information Update: 16 Jan 2024
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action SOS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Hanmi Pharmaceutical plans a clinical trial for Solid tumours in early 2024
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 26 Apr 2022 HM 99462 is available for licensing as of 26 Apr 2022. https://www.hanmipharm.com/ehanmi/handler/Business-GlobalOut